… Objective/Rationale: While the oral medications to treat PD are often quite effective in treating the … is administered. Participants should not feel anything uncomfortable with the stimulation due to the low levels of … treatment, subjects will return to the clinic for five visits over 14 weeks to determine the response to treatment …

… Home Page Cancel Register for Webinar From iPhone to Genome: How Patient Data is Changing Parkinson's Research … had PD I am a researcher, clinician or work with the PD community Other   Diagnosis Date ${selected} Jan Feb Mar Apr … 1 hr Time: 12:00 pm ET Smartphone apps and online study portals offer a new way for people to participate in …

… Discouraging news this week for the Parkinson’s community, as drug giant Merck announced that they will … their program developing a novel therapy for PD called preladenant.   “This announcement is especially … the drug development pipeline, and the clinical results to date had been quite encouraging,” explains Maurizio …

… Last night, Michael J. Fox made his last visit to the Late Show with David Letterman . Michael joined a … it, and you learn about it, you realize you're part of a community and you can make a difference — and you can get on …

… protein leucine-rich repeat kinase 2, or LRRK2 , is fast becoming a target of major interest for researchers looking to develop Parkinson’s disease (PD) drugs, for a couple of … inhibitor could improve the function of the LRRK2 kinase to prevent Parkinson’s from arising or progressing. Genentech …

… with Medicated Parkinsonian Patients Promising Outcomes of Original Grant : In keeping with our original … in the original application, the pre-clinical model proved to be sufficiently stable as to allow an A-B-A design, and … direct acting agonist, ropinerole will emulate pramipexole, whereas L-DOPA, which acts to presynaptically enhance DA …